Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Male Participants

NCT ID: NCT03814642

Last Updated: 2019-10-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-01-21
• Study Completion Date: 2019-07-22

Brief Summary

This study aims to evaluate the influence of tegoprazan on the pharmacodynamics of clopidogrel according to CYP2C19 genotypes following co-administration of tegoprazan and clopidogrel in healthy male volunteers.

Detailed Description

Evaluation Criteria:

• Pharmacodynamic assessments using P2Y12 assay
• Safety assessments with adverse event monitoring including subjective/objective symptoms, physical examination, vital signs, electrocardiogram, and laboratory test

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Clopidogrel 75 mg

Oral administration of clopidogrel 75 mg tablet once daily for 7 days

Group Type: ACTIVE_COMPARATOR

Clopidogrel 75 mg

Intervention Type: DRUG

Clopidogrel 75 mg tablet

Clopidogrel 75 mg + Tegoprazan 50 mg

Oral administration of clopidogrel 75 mg tablet and tegoprazan 50 mg tablet once daily for 7 days

Group Type: EXPERIMENTAL

Clopidogrel 75 mg

Intervention Type: DRUG

Clopidogrel 75 mg tablet

Tegoprazan 50 mg

Intervention Type: DRUG

Tegoprazan 50 mg tablet

Clopidogrel 75 mg + Esomeprazole 20 mg

Oral administration of clopidogrel 75 mg tablet and esomeprazole 20 mg tablet once daily for 7 days

Group Type: EXPERIMENTAL

Clopidogrel 75 mg

Intervention Type: DRUG

Clopidogrel 75 mg tablet

Esomeprazole 20 mg

Intervention Type: DRUG

Esomeprazole 20 mg tablet

Interventions

Clopidogrel 75 mg

Clopidogrel 75 mg tablet

Intervention Type: DRUG

Tegoprazan 50 mg

Tegoprazan 50 mg tablet

Intervention Type: DRUG

Esomeprazole 20 mg

Esomeprazole 20 mg tablet

Intervention Type: DRUG

Other Intervention Names

Plavix; K-CAB; Nexium

Eligibility Criteria

Inclusion Criteria

• Healthy adult males aged ≥ 19 years and ≤ 50 years on the date of the written informed consent
• Body weight of ≥ 55.0 kg and ≤ 90.0 kg, with body mass index (BMI) of ≥ 18.0 kg/m2 and ≤ 27.0 kg/m2 at the time of screening
• Helicobacter pylori negative
• Voluntarily decided to participate in the study and provided written informed consent before any screening procedure
• Judged by the investigator to be eligible for this study based on physical examination, laboratory test, inquiry, etc.

Exclusion Criteria

• Has a history of or currently has clinically significant liver, kidney, nervous system, respiratory system, endocrine system, blood, cardiovascular system, urinary system, or psychiatric disease or tumor
• Has a history of or currently has gastrointestinal disorder (gastrointestinal ulcer, gastritis, stomach cramps, gastroesophageal reflux disease, Crohn's disease, etc.) that may influence the safety and pharmacodynamic assessments of the investigational product
• Has a history of gastrointestinal surgery (except simple appendectomy and hernia surgery)
• Hypersensitivity to drugs including the ingredients of the investigational product and other drugs (aspirin, antibiotics, etc.) or a history of clinically significant hypersensitivity
• Positive serological test including hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
• Blood total bilirubin, AST (GOT), and ALT (GPT) levels greater than 1.5x of the upper limit of normal range at screening
• Platelet, PT and aPTT levels outside the upper/lower limit of normal range by 10% at screening
• P2Y12 Reaction Unit (PRU) by P2Y12 assay outside the upper/lower limit of normal range by 10% at screening
• *17 allele by CYP2C19 genotyping (Ultrarapid metabolizer)
• Systolic blood pressure < 90 mmHg or > 140 mmHg, diastolic blood pressure < 50 mmHg or > 95 mmHg, or pulse rate < 45 beats/minute or > 100 beats/minute when vital signs are measured in sitting position after resting for at least 5 minutes during screening
• QTc > 450 msec, PR interval > 200 msec, QRS interval > 120 msec, and other clinically significant findings on electrocardiogram at screening
• Has a history of or positive urine screening for drug abuse
• Administration of any prescription drugs or herbal medicine within 2 weeks prior to the expected date of the first dose, or administration of any over-the-counter (OTC) drug, health functional food or vitamin within 1 week prior to the expected date of the first dose (However, can participate in the study if otherwise decided eligible by the investigator)
• Participation in other clinical study or bioequivalence study to receive an investigational product within 3 months prior to the expected date of the first dose
• Donation of whole blood within 2 months or apheresis/receipt of blood transfusion within 1 month prior to the expected date of the first dose
• Excessive caffeine intake (> 5 units/day) or persistent alcohol intake (> 21 units/week, 1 unit = 10 g of pure alcohol), or inability to abstain from drinking during hospitalization period
• Smoking for more than 3 months prior to the study or inability to cease smoking throughout the study
• Inability to refrain from grapefruit-containing food from 24 hours before admission to discharge
• Inability to refrain from caffeine-containing food (coffee, tea (black tea, green tea, etc.), carbonated drink, coffee-flavored milk, nutritional tonic, etc.) from 24 hours before admission to discharge
• Inability to use a medically acceptable method of contraception throughout the study. Medically acceptable methods of contraception include use of intrauterine device with established failure rate of contraception by spouse (or partner), concomitant use of barrier method (for male or for female) and spermicide, or surgical procedure on subject himself or his partner (vasectomy, tubal resection/ligation, hysterectomy)
• Considered ineligible to participate in the study by the investigator based on laboratory test results or other reasons

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

HK inno.N Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

In-Jin Jang

Role: PRINCIPAL_INVESTIGATOR

Seoul National University Hospital, Dept. of Clinical Pharmacology

Locations

Seoul National University Hospital, Clinical Trial Center

Seoul, , South Korea

Countries

South Korea

Other Identifiers

CJ_APA_110

Identifier Type: -

Identifier Source: org_study_id